Sun Pharma Gears Up for Q3 Reveal on 31st January; Check Key Expectations Here

Click and Sign Up to Get Live Updates on Q3 Results 

Sun Pharma’s Q3 results FY26 are scheduled to be announced on 31st January 2026. Financial analysts anticipate an increase in revenue due to higher sales and a significant rise in PAT.

Sun Pharma Q3 Results 2026 Preview

• Sun Pharma’s revenue is expected to be in the range of ₹13,675.46 crore, a 2.89% YoY increase. 
• Profit After Tax, or PAT, is projected to fall by 4.50% YoY. 
• Net profit is ₹2,903.38 crore, a fall 4.50% YoY 
• EBITDA to rise 21.91%

Sun Pharma Share Performance 

• Over the past six months, Sun Pharma’s share price has fallen by 8.01% to ₹1,595.00.
• Moreover, over the past year, the stock has increased by 1,595.00%.
• Despite this weak short-term performance, Sun Pharma’s stock has delivered a financially sound 172.09% return over the past 5 years.
• As of 30th January 2026, the stock traded at ₹1,595.00 per share.

Key Factors to Watch for Sun Pharma Q3 Results FY26 

• Revenue Growth & Geographic Mix: Trend in overall sales growth, particularly performance in India, the U.S. and emerging markets, where pricing and market dynamics differ.
  
• EBITDA & Profit Margins: Changes in EBITDA margins and net profit, influenced by cost control, R&D spend and regional pricing pressures.
  
• Specialty Portfolio Momentum: Traction of specialty drugs (higher-margin products) versus traditional generics, especially in regulated markets.
  
• R&D & Pipeline Updates: Spending trends and progress on new product launches, ANDA/NDA approvals and clinical pipeline catalysts.
  
• US Market Pricing & Regulatory Trends: U.S. generics pricing behaviour and any regulatory outcomes (e.g., inspections/approvals) that could impact near-term earnings. 

Final Thoughts

Sun Pharma will announce its Q3 FY26 results on 30th January 2026. Analysts expect 2.89% YoY revenue growth, a 4.50% fall in PAT, and a 1.91% rise in EBITDA. Sun Pharma focuses on being a leading global speciality and generics pharmaceutical company by expanding its speciality drug portfolio and differentiated complex generics, investing in R&D and innovation, strengthening branded and regulated markets (especially the U.S. and India), and ensuring broad global reach with quality-compliant manufacturing and strategic partnerships.

Disclaimer: Investment in the share market is subject to risk. This news article is for informational purposes only. Conduct your own research before investing in shares and other securities.

Download the Univest iOS App or Univest Android App to get daily stock recommendations and insightful research pieces!

Recent Articles

Capital Small Finance Bank Gears Up for Q3 Reveal on 29th January; Check Key Expectations Here

Carborundum Universal Gears Up for Q3 Reveal on 29th January; Check Key Expectations Here

Capri Global Capital Gears Up for Q3 Reveal on 29th January; Check Key Expectations Here

Digitide Solutions Gears Up for Q3 Reveal on 29th January; Check Key Expectations Here

Flair Writing Industries Gears Up for Q3 Reveal on 29th January; Check Key Expectations Here

GHCL Gears Up for Q3 Reveal on 29th January; Check Key Expectations Here

Apar Industries Gears Up for Q3 Reveal on 29th January; Check Key Expectations Here

Apollo Pipes Gears Up for Q3 Reveal on 29th January; Check Key Expectations Here